ReviewMarine drugs2019
The "Utility" of Highly Toxic Marine-Sourced Compounds.
Review in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated CyanobacteriumJournal of natural products · 2025Article
- Cortistatin and plakinamine steroidal alkaloids from the marine sponges of the genusRSC advances · 2025Review
- Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for Glioblastoma.Current neurology and neuroscience reports · 2024Review
- First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Antimicrobial Activity of the Secondary Metabolites Isolated from a South African Red Seaweed,Molecules (Basel, Switzerland) · 2023Article
- Antibody-Drug Conjugates Containing Payloads from Marine Origin.Marine drugs · 2022Review
- Recent Discoveries on Marine Organism Immunomodulatory Activities.Marine drugs · 2022Review
- Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.Cell reports · 2022Article
- Biomaterials from the sea: Future building blocks for biomedical applications.Bioactive materials · 2021Review
- Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.Cancers · 2021Review
- Novel Marine Secondary Metabolites Worthy of Development as Anticancer Agents: A Review.Molecules (Basel, Switzerland) · 2021Review
- Development of Marine-Derived Compounds for Cancer Therapy.Marine drugs · 2021Review
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics.Angewandte Chemie (International ed. in English) · 2020Article
- Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.Marine drugs · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently a few compounds isolated from marine sources have become drugs, mainly directed towards cancer and pain. Compounds from marine sources have exquisite potencies against eukaryotic cells, as they act as protective agents against attack by predators in the marine environment. Their toxicities act as a "double-edged sword" as they are often too toxic for direct use in humans and thus have to be chemically modified. By linking suitably modified compounds to monoclonal antibodies directed against specific epitopes in mammalian cancer cells, they can be delivered to a specific cell type in humans. This review updates and extends an article published in early 2017, demonstrating how by careful chemical modifications, highly toxic compounds, frequently peptidic in nature, can be utilized as antitumor drug candidates. The antibody-drug- conjugates (ADCs) discussed are those that are currently in clinical trials listed in the NIH Clinical Trials Registry as, "currently active, recruiting or in some cases, recently completed". There are also some ADCs discussed that are at the advanced preclinical stage, that in some cases, are repurposing current drug entities, and the review finishes with a short discussion of the aplyronines as potential candidate warheads as a result of scalable synthetic processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.